| Literature DB >> 30103687 |
Katarzyna Górowska-Kowolik1, Agata Chobot2, Jarosław Kwiecień3.
Abstract
BACKGROUND: Anorexia nervosa (AN) concerns approximately up to 1.8% of the pediatric female population. One of the complications that can occur in the course of this disease is acute liver failure. This study's objective was to assess the usefulness of the 13C labeled Methacetin Breath Test (MBT) in the diagnostics of the liver function in girls with eating disorders.Entities:
Keywords: Anorexia nervosa; Cytochrome P450; Liver function; Methacetin breath test
Mesh:
Substances:
Year: 2018 PMID: 30103687 PMCID: PMC6090712 DOI: 10.1186/s12876-018-0856-1
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 3.067
Diagnostic criteria of anorexia nervosa (according to DSM-5) [4, 27]
| A. Restriction of energy intake relative to requirements leading to a significantly low body weight in the context of age, sex, developmental trajectory, and physical health. | |
| B. Intense fear of gaining weight or becoming fat, or persistent behaviors affecting weight loss even though underweight. | |
| C. Disturbance in the way in which one’s body weight or shape is experienced, undue influence of body weight or shape on self-evaluation, or denial of the seriousness of the current low body weight. | |
Comparison of anthropometric parameters of the AN and control group
| Parameter | Females with AN | Control group |
|
|---|---|---|---|
| Age (years) | 14.7 ± 1.48 | 15.1 ± 1.62 | 0.258 |
| Weight (kg) | 41.23 ± 5.61 | 54.58 ± 6.12 | < 0.001 |
| Weight percentile | 12 ± 15 | 53 ± 21 | < 0.001 |
| Height (cm) | 162.2 ± 6.1 | 165.0 ± 5.3 | 0.030 |
| Height percentile | 48 ± 28 | 59 ± 26 | 0.084 |
| BMI (kg/m2) | 15.70 ± 1.84 | 20.08 ± 1.49 | < 0.001 |
| BMI percentile | 8 ± 12 | 50 ± 19 | < 0.001 |
Comparison of laboratory parameters characterizing the study and control group (reference values of each parameter are in the brackets)
| Parameter and normal range | Patients with AN | Control group |
|
|---|---|---|---|
| Bilirubin (3.4–22 umol/l) | 10,33 ± 5151 | 16.48 ± 13.19 | 0.008 |
| AST (0–40 U/l) | 24.0 ± 14.11 | 17.6 ± 3.06 | 0.007 |
| ALT (0–41 U/l) | 25.0 ± 22.13 | 11.9 ± 3.90 | < 0.001 |
| INR (0.9–1.3) | 1.10 ± 0.083 | 1.02 ± 0.056 | < 0.001 |
| GGTP (10–78 U/l) | 18.6 ± 14.35 | 12.7 ± 5.65 | 0.018 |
| Hb (12–15 g/dl) | 13.64 ± 1.094 | 13.39 ± 0.896 | 0.241 |
Fig. 1Comparison of 13C methacetin metabolism, presented as mean of the total percent of the 13CO2 dose recovery (% cumulative dose, CD), in the study and control group; ANOVA variance analysis (p < 0.05)
Fig. 2Post-hoc RIR Tukey’s test for the analyzed variable (Cum dose) 10′-40′ in the study and control group, p < 0.05
Fig. 3Post-hoc RIR Tukey’s test for the analyzed variable (Cum dose) 50′-120′ in the study and control group, p < 0.05
Fig. 4Analysis of the dose/h mean values in both groups as well as its graphic interpretation